-
eLife: Studies have found that destroying the interoperability between MYC and HCF-1 can ablate tumors
Time of Update: 2021-02-10
MYC cancer proteins are the main driver of most human cancers, causing nearly one-third of cancer-related deaths each year. it can act as both transcription activation factor and deterrent factor, re
-
Gastrointest Endosc: The risk of Barrett's esobar developing into an esothy tube tumor!
Time of Update: 2021-02-10
study process included patients diagnosed with BE-IND from two academic centers who received endoscopic follow-up (FU) of up to 1 year or more if there was no evidence of heterogeneity in the past.
-
Three haze five gas "let China's lung cancer high incidence! Professor Xiuyi summarized the experience of lung cancer prevention and treatment
Time of Update: 2021-02-10
By 2020, the total number of cancer cases worldwide has exceeded 20 million and the number of cancer deaths per year will exceed 10 million, with lung cancer ranking first in terms of morbidity and mo
-
NEJM: Research on genetic assessment of breast cancer-related risks
Time of Update: 2021-02-10
study found that truncation mutations in ATMs, BRCA1, BRCA2, CHEK2 and PALB2, which cause early termination of protein transcription, were associated with an overall risk of breast cancer, with p-values of 0.000 1, while truncated mutations in the BARD1, RAD51C, RAD51D, and TP53 genes were associated with an overall risk of breast cancer, with P-values of 0.05 and Bayes error detection rates of 0.05.
-
ESMO Open: Are older cancer patients at higher risk of side effects from immunosuppressant treatment?
Time of Update: 2021-02-04
, older cancer patients are heterogeneic and the risk-benefit assessment of specific treatment strategies is difficult.
in short, older cancer patients do not have any higher adverse reactions to CPI treatment than younger people.
-
ACS Nano: "Sprinkle urine photo"! AI diagnoses prostate cancer with latest breakthrough in just 20 minutes, nearly 100% accuracy
Time of Update: 2021-02-04
In this latest study, the Korea Institute of Science and Technology announced that a team of researchers led by Dr. Kwan Hyi Lee of the Center for Biomass Research and Professor In Gab Jeong of Asan Medical Center has developed a technology to diagnose prostate cancer from urine in just 20 minutes with nearly 100% accuracy by introducing AI analysis into ultra-sensitive biosensors based on electrical signals.
-
J Clin Oncol: Low-dose radiotherapy combined with cisplatin is effective in treating HPV-related oral and pharyngophageal cancer
Time of Update: 2021-02-04
to enter Phase III, the treatment group's 2-year progress-free survival rate (PFS) must be higher than the historical control rate of 85% and the 1-year average MD Anderson Dysphagy Index (MDADI≥60.
-
BMC Medicine: A healthy lifestyle reduces the risk of cancer and heart metabolic disease
Time of Update: 2021-02-04
the definition of multiple cancer-heart metabolism refers to a person who subsequently develops at least two diseases, including cancer in any part, cardiovascular disease, and type 2 diabetes.
: A healthy lifestyle can reduce the risk of cancer, heart metabolic disease, and multiple onset.
-
ESMO Open: Immunosuppressant therapy can reduce the incidence of secondary secondary primary cancer
Time of Update: 2021-02-04
study aims to explore the effects of immuno-checkpoint inhibitors (ICI) on secondary SPC in FPC patients of different ages, cancer types, and treatments.
-
Eur J Cancer: Tumor-soaked lymphocyte density is positively related to the prognostic prognosticity of NSCLC patients with immunotherapy!
Time of Update: 2021-02-04
summary, in the real immunotherapy queue of NSCLC patients, high TIL was associated with a good prognosis, but independent of the prognosis of patients with chemotherapy, suggesting that TIL could be used to screen patients suitable for immunotherapy.
-
Pemigatinib treats advanced bile tube cancer with FGFR2 fusion or rearmissing, chMP said positively
Time of Update: 2021-02-04
if approved, pemigatinib will be the first targeted treatment in the EU for patients with non-removable localized advanced or metastatic bile tube cancer who are fused or rearmed with FGFR2.
-
J Clin Oncol: Full pelvic preventive radiotherapy can further improve the prognostic prognostication of patients with local advanced prostate cancer than pure prostate radiotherapy
Time of Update: 2021-02-04
November 2011-August 2017, a total of 224 patients were randomly divided into two groups: PORT-114, WPRT-110.
, preventive pelvic radiation therapy for high-risk localized advanced prostate cancer improved BFFS and DFS in patients compared to PORT, but did not appear to have a significant effect on OS.
-
Pryor Benchmark Technology and Baitu Shengke reached a strategic cooperation to jointly build a biocalculation ecology, enabling multi-group research on tumors
Time of Update: 2021-02-03
Baitusheng is committed to building an international leading level of multi-group ecology, through independent research and development and global investment, a variety of cutting-edge technologies and professional teams at home and abroad, jointly promote multi-level, multi-dimensional, continuous clinical large-queue analysis, to help cancer, self-exemption, aging-related diseases metabolic law mining, new biomarkers and target mining, accelerate the creation of more innovative drugs and diagnostic products.
-
Repotrectinib treats ROS1-positive non-small cell lung cancer with ORR up to 93%
Time of Update: 2021-02-03
Mohammad Hirmand, chief medical officer of Turing Point Therapeutics, said: "These interim data confirm our belief that repotrectinib has the potential to be the best treatment for patients with ros1-positive advanced non-small cell lung cancer."
-
Hematological toxic side effects associated with epithelial ovarian cancer chemotherapy and PARPi therapy: clinical manifestations, diagnosis and management
Time of Update: 2021-02-03
However, most patients will relapse, and in recent years poly-ADP-UC polymerase inhibitors (PARPi) have been developed as new and effective anti-cancer therapies, especially for carriers of mutations in the breast cancer gene (BRCA1/ BRCA2).
-
Sexually active young women have the highest rates of HPV infection, and experts are calling for girls aged 9-14 to be vaccinated
Time of Update: 2021-02-03
Wu Ruifang said it is best to get a cervical cancer vaccine before the first sex without exposure to the HPV virus, women after the age of 9 can be vaccinated.
-
China's State Drug Administration (NMPA) awards sothorasib "breakthrough therapy" for advanced non-small cell lung cancer
Time of Update: 2021-02-03
Amjin announced today that its research KRASG12C inhibitor sotorasib has been awarded the "Breakthrough Therapy Title" by the Drug Review Center (CDE) of china's State Drug Administration (NMPA).
-
J Clin Oncol: Encorafenib situxy monoanti, BRAF V600E Mutant Metastatic Colorectal Cancer Patients New Options!
Time of Update: 2021-02-03
in a preliminary analysis previously reported, the encorafenib-biniteni-sytoci monoanti (ENCO/BINI/CETUX; triple) and encorafenib-sytoci monoantigen (ENCO/CETUX; double)programmes improved the total survival rate (OS) and objective response rate (ORR) of such patients compared to standard treatment.
-
Acta Neuropathologica: Multigroup molecular maps reveal potential targeting abnormalities common to multiple histology of brain metastasis
Time of Update: 2021-02-03
To identify and describe these mechanisms, the study used all-exon sequencing, mRN-seq, and introphic protein array analysis to perform genomic, transcriptional, and proteomic analysis of lung, breast and renal cell carcinomas, including BM and patient-matched primary or extracranial metastasis tissue.
multiple immunofluorescence analysis confirmed significant T-cell depletion in BM, indicating a fundamental change in the immune micro-environment.
-
J Clin Oncol: Enhanced topical radiotherapy improves disease control in patients with limited prostate cancer
Time of Update: 2021-02-03
addition, intensive radiotherapy for tumor lesions in the prostate can further improve bDFS in patients with local high-risk prostate cancer on the basis of standard in-body radiotherapy of the whole prostate without affecting toxicity and quality of life.
